Research graph
References from BCMA-Targeted T-Cell Engager Therapy for Refractory Pemphigus. Local targets link to admitted publications; unresolved targets remain external evidence.
Temporal outcomes after rituximab therapy for pemphigus vulgaris.
10.1016/j.jid.2021.09.013 · 2022 · External reference
Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.
10.1038/jid.2014.291 · 2015 · External reference
BCMA-targeted T-cell-engager therapy for autoimmune disease.
10.1056/nejmc2408786 · 2024 · External reference
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
10.1038/nrrheum.2011.1 · 2011 · External reference
Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis.
10.1016/j.jid.2017.05.032 · 2017 · External reference
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
10.1016/s0140-6736(17)30070-3 · 2017 · External reference
